Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622765 | 1.00 | GRM8 (0.42) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL5964600 | 1.00 | GRM8 (0.42) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL3850920 | 1.00 | GRM8 (0.42) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL15542060 | 0.93 | BLM (0.41) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL1373235 | 0.83 | ALDH1A1 (0.36) | CYP1A2DPP4DPP8DPP9BHMT | |
| SCHEMBL2467621 | 0.82 | BHMT (0.48) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL15541251 | 0.81 | BHMT (0.37) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL3213831 | 0.76 | ADRA1A (0.43) | CYP1A2LMNABLMCYP2D6NFKB1 | |
| SCHEMBL7918137 | 0.74 | NOD1 (0.39) | DPP4DPP8DPP9ENPEPALDH1A1 | |
| SCHEMBL2392741 | 0.73 | LMNA (0.44) | CYP1A2LMNABLMCYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4305161-A1 | ANTIBACTERIAL POLYPEPTIDES | Novalysin AB (SE) | 2024-01-17 | — | — | EP | claimed |
| WO-2014001572-A1 | COMPOSITION FOR USE IN MYCOBACTERIA THERAPY | LYSANDO AG (LI) | 2014-01-03 | — | — | WO | claimed |
| WO-2014001570-A1 | COMPOSITION FOR USE IN MYCOBACTERIA VACCINATION | LYSANDO AG (LI) | 2014-01-03 | — | — | WO | claimed |
| WO-2014001571-A1 | COMPOSITION FOR USE IN MYCOBACTERIA DIAGNOSIS | LYSANDO AG (LI) | 2014-01-03 | — | — | WO | claimed |
| EP-4297762-A1 | COMPOSITIONS AND METHODS FOR REDUCING CYTOKINE EXPRESSION | Evelo Biosciences, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4284400-A1 | PREVOTELLA EXTRACELLULAR VESICLE PREPARATIONS | Evelo Biosciences, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022164806-A1 | PREVOTELLA EXTRACELLULAR VESICLE PREPARATIONS | EVELO BIOSCIENCES, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20210145975-A1 | IMMUNOGENIC COMPOUND | ALTIMMUNE UK LTD (GB) | 2021-05-20 | — | — | US | disclosed |
| US-10849984-B2 | Immunogenic compound | ALTIMMUNE UK LIMITED (GB) | 2020-12-01 | — | — | US | disclosed |
| US-20200038519-A1 | IMMUNOGENIC COMPOUND | ALTIMMUNE UK LIMITED | 2020-02-06 | — | — | US | disclosed |
| US-10434183-B2 | Immunogenic compound | Altimmune UK Ltd. (GB) | 2019-10-08 | — | — | US | disclosed |
| US-20190125889-A1 | IMMUNOGENIC COMPOUND | ALTIMMUNE UK LIMITED (GB) | 2019-05-02 | — | — | US | disclosed |
| US-9962453-B2 | Immunogenic compound | ALTIMMUNE UK LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| WO-2018053508-A1 | METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20160310603-A1 | IMMUNOGENIC COMPOUND | ALTIMMUNE UK LIMITED (GB) | 2016-10-27 | — | — | US | disclosed |
| WO-2015145463-A1 | PHAGE-DERIVED COMPOSITIONS FOR IMPROVED MYCOBACTERIAL THERAPY | GANGAGEN, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| EP-1979488-A4 | IMMUNOSTIMULATORY COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERGIC RECEPTOR, AND CYTOKINE RECEPTOR AGOINSTS FOR VACCINES AND TUMOR IMMUNOTHERAPY | UNIV CALIFORNIA (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1979488-A2 | IMMUNOSTIMULATORY COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERGIC RECEPTOR, AND CYTOKINE RECEPTOR AGOINSTS FOR VACCINES AND TUMOR IMMUNOTHERAPY | The Regents of the University of California Office of Technology Transfer (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007120368-A2 | IMMUNOSTIMULATORY COMBINATIONS FOR VACCINE ADJUVANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038519-A1 | IMMUNOGENIC COMPOUND | CD74, HLA-DRB1, MICA | GRM8 2096/4885GRM6 1768/4885GRIN2D 4506/4885 |
| US-10434183-B2 | Immunogenic compound | CD74, HLA-DRB1, MICA | GRM8 2096/4885GRM6 1768/4885GRIN2D 4506/4885 |
| US-20190125889-A1 | IMMUNOGENIC COMPOUND | CD74, HLA-DRB1, MICA | GRM8 2096/4885GRM6 1768/4885GRIN2D 4506/4885 |
| US-10849984-B2 | Immunogenic compound | CD74, HLA-DRB1, MICA | GRM8 2096/4885GRM6 1768/4885GRIN2D 4506/4885 |
| US-20210145975-A1 | IMMUNOGENIC COMPOUND | CD74, HLA-DRB1, MICA | GRM8 2096/4885GRM6 1768/4885GRIN2D 4506/4885 |
| US-20160310603-A1 | IMMUNOGENIC COMPOUND | CD74, HLA-DRB1, MICA | GRM8 2096/4885GRM6 1768/4885GRIN2D 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.